Workforce participation in relation to cancer diagnosis, type and stage: Australian population-based study of 163,556 middle-aged people.


Journal

Journal of cancer survivorship : research and practice
ISSN: 1932-2267
Titre abrégé: J Cancer Surviv
Pays: United States
ID NLM: 101307557

Informations de publication

Date de publication:
04 2022
Historique:
received: 12 10 2020
accepted: 07 04 2021
pubmed: 20 5 2021
medline: 12 4 2022
entrez: 19 5 2021
Statut: ppublish

Résumé

To quantify the relationship of cancer diagnosis to workforce participation in Australia, according to cancer type, clinical features and personal characteristics. Questionnaire data (2006-2009) from participants aged 45-64 years (n=163,556) from the population-based 45 and Up Study (n=267,153) in New South Wales, Australia, were linked to cancer registrations to ascertain cancer diagnoses up to enrolment. Modified Poisson regression estimated age- and sex-adjusted prevalence ratios (PRs) for non-participation in the paid workforce-in participants with cancer (n=8,333) versus without (n=155,223), for 13 cancer types. Overall, 42% of cancer survivors and 29% of people without cancer were out of the workforce (PR=1.18; 95%CI=1.15-1.21). Workforce non-participation varied substantively by cancer type, being greatest for multiple myeloma (1.83; 1.53-2.18), oesophageal (1.70; 1.13-2.58) and lung cancer (1.68; 1.45-1.93) and moderate for colorectal (1.23; 1.15-1.33), breast (1.11; 1.06-1.16) and prostate cancer (1.06; 0.99-1.13). Long-term survivors, 5 or more years post-diagnosis, had 12% (7-16%) greater non-participation than people without cancer, and non-participation was greater with recent diagnosis, treatment or advanced stage. Physical disability contributed substantively to reduced workforce participation, regardless of cancer diagnosis. Cancer survivors aged 45-64 continue to participate in the workforce. However, participation is lower than in people without cancer, varying by cancer type, and is reduced particularly around the time of diagnosis and treatment and with advanced disease. While many cancer survivors continue with paid work, participation is reduced. Workforce retention support should be tailored to survivor preferences, cancer type and cancer journey stage.

Identifiants

pubmed: 34008147
doi: 10.1007/s11764-021-01041-7
pii: 10.1007/s11764-021-01041-7
pmc: PMC8964624
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

461-473

Subventions

Organisme : National Health and Medical Research Council
ID : 1139539

Informations de copyright

© 2021. The Author(s).

Références

Support Care Cancer. 2014 Jan;22(1):181-7
pubmed: 24026981
Int J Epidemiol. 2008 Oct;37(5):941-7
pubmed: 17881411
J Health Econ. 2018 Mar;58:151-175
pubmed: 29486331
J Cancer Surviv. 2008 Mar;2(1):20-32
pubmed: 18648984
J Cancer Surviv. 2017 Aug;11(4):453-461
pubmed: 28213769
BMC Med Res Methodol. 2010 Apr 01;10:26
pubmed: 20356408
Occup Med (Lond). 2019 Apr 13;69(2):126-132
pubmed: 30882861
Eur J Cancer Care (Engl). 2017 Sep;26(5):
pubmed: 28771857
Med Care. 2007 May;45(5 Suppl 1):S32-8
pubmed: 17443117
J Health Econ. 2011 May;30(3):505-14
pubmed: 21429606
Support Care Cancer. 2007 May;15(5):515-23
pubmed: 17120068
Health Econ. 2017 May;26(5):671-684
pubmed: 27045223
J Cancer Surviv. 2015 Jun;9(2):349-60
pubmed: 25492237
Cancer. 2015 Mar 1;121(5):758-65
pubmed: 25369293
Eur J Public Health. 2013 Feb;23(1):116-22
pubmed: 22227027
J Thorac Oncol. 2012 Jan;7(1):64-70
pubmed: 22134070
Support Care Cancer. 2012 Sep;20(9):1957-64
pubmed: 22033835
J Cancer Surviv. 2020 Apr;14(2):114-134
pubmed: 31858379
Chron Respir Dis. 2012 Feb;9(1):39-47
pubmed: 22308553
Int J Epidemiol. 2013 Aug;42(4):1012-4
pubmed: 24062287
Psychooncology. 2005 Mar;14(3):221-6
pubmed: 15386773
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648
PLoS One. 2009;4(1):e4191
pubmed: 19142227
Psychol Med. 2002 Aug;32(6):959-76
pubmed: 12214795
Psychooncology. 2017 Sep;26(9):1354-1360
pubmed: 27862573

Auteurs

Joanne Thandrayen (J)

National Centre for Epidemiology and Population Health, Research School of Population Health, Australian National University, Canberra, Australian Capital Territory, Australia. Joanne.Thandrayen@anu.edu.au.

Grace Joshy (G)

National Centre for Epidemiology and Population Health, Research School of Population Health, Australian National University, Canberra, Australian Capital Territory, Australia.

John Stubbs (J)

CanSpeak, Sydney, New South Wales, Australia.

Louise Bailey (L)

Primary Care Collaborative Cancer Clinical Trials Group Community Advisory Group, Melbourne, Victoria, Australia.
Psycho-oncology Cooperative Research Group Community Advisory Group, Camperdown, New South Wales, Australia.

Phyllis Butow (P)

The University of Sydney, Sydney, New South Wales, Australia.

Bogda Koczwara (B)

Flinders University and Flinders Medical Centre, Adelaide, South Australia, Australia.

Rebekah Laidsaar-Powell (R)

The University of Sydney, Sydney, New South Wales, Australia.

Nicole M Rankin (NM)

The University of Sydney, Sydney, New South Wales, Australia.

Katie Beckwith (K)

National Centre for Epidemiology and Population Health, Research School of Population Health, Australian National University, Canberra, Australian Capital Territory, Australia.

Kay Soga (K)

National Centre for Epidemiology and Population Health, Research School of Population Health, Australian National University, Canberra, Australian Capital Territory, Australia.

Amelia Yazidjoglou (A)

National Centre for Epidemiology and Population Health, Research School of Population Health, Australian National University, Canberra, Australian Capital Territory, Australia.

Muhammad Shahdaat Bin Sayeed (MS)

National Centre for Epidemiology and Population Health, Research School of Population Health, Australian National University, Canberra, Australian Capital Territory, Australia.

Karen Canfell (K)

The Daffodil Centre, The University of Sydney, Sydney, New South Wales, Australia.
Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia.

Emily Banks (E)

National Centre for Epidemiology and Population Health, Research School of Population Health, Australian National University, Canberra, Australian Capital Territory, Australia.
Sax Institute, Glebe, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH